Related Experiment Videos

[Congenital myasthenia with esophageal involvement]

N Beydon1, C Faure, M Mayer

  • 1Service de Pédiatrie Générale, Hôpital Robert-Debré, Paris.

Archives Francaises De Pediatrie
|March 1, 1993
PubMed

Insights

Neonatal myasthenia gravis can cause unrecognized esophageal dysfunction and gastroesophageal reflux. Treatment with neostigmine improved both myasthenia symptoms and esophageal function in an infant.

Area of Science:

  • Pediatric Neurology
  • Gastroenterology
  • Clinical Medicine

Background:

  • Persistent neonatal myasthenia gravis (MG) can present with subtle symptoms, delaying diagnosis.
  • Esophageal dysfunction associated with neonatal MG has not been previously investigated.

Observation:

  • A case of infant gastroesophageal reflux (GER) initially untreated.
  • Development of ptosis, extraocular muscle weakness, and proximal limb weakness at 8 months.
  • Rapid symptom resolution with neostigmine, indicating a neuromuscular junction disorder.
  • Neuromuscular tests confirmed post-synaptic defects corrected by edrophonium chloride.
  • Absence of acetylcholine receptor antibodies in the patient and her mother.
  • Esophageal pH monitoring revealed significant acid reflux episodes.
  • Esophageal manometry showed abnormalities in both striated and smooth muscle, responsive to neostigmine.

Findings:

  • Myasthenia gravis can manifest with significant esophageal dysmotility, including impaired esophageal clearance and reduced lower esophageal sphincter pressure.
  • Neostigmine effectively treated both the neuromuscular and esophageal symptoms in this infant.

Implications:

  • This case highlights the potential for neonatal myasthenia gravis to cause or exacerbate gastroesophageal reflux.
  • Early recognition and treatment of MG may prevent or alleviate associated esophageal complications.
  • Further research into the link between MG and esophageal dysfunction is warranted.
Abstract

Related Concept Videos